The trial's primary end point was the reduction in the number of gadolinium-enhancing lesions.

试验的主要终点是钆增强病变数目的减少。

youdao

The trial's primary end point was the reduction in the number of gadolinium-enhancing lesions.

试验的主要终点是钆增强病变数目的减少。

youdao